Oxford Biomedica PLC — Investor Relations & Filings
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| AGM Minutes | 2026-05-07 | English | |
| Result of AGM | 2026-05-07 | English | |
| Total Voting Rights | 2026-05-01 | English | |
| Admission to Trading | 2026-04-30 | English | |
| Admission to Trading Application | 2026-04-27 | English | |
| Launch of viral vector fast-track offering | 2026-04-13 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 43633533 | AGM Minutes | 2026-05-07 | English | ||
| 43197184 | Result of AGM | 2026-05-07 | English | ||
| 39399113 | Total Voting Rights | 2026-05-01 | English | ||
| 39034920 | Admission to Trading | 2026-04-30 | English | ||
| 37376856 | Admission to Trading Application | 2026-04-27 | English | ||
| 34392469 | Launch of viral vector fast-track offering | 2026-04-13 | English | ||
| 33897356 | Grant of Awards | 2026-04-08 | English | ||
| 33128279 | Total Voting Rights | 2026-04-01 | English | ||
| 33090029 | Annual financial and audit reports | 2026-03-30 | English | ||
| 33090024 | Annual financial and audit reports | 2026-03-30 | English | ||
| 33090019 | 2026 Annual General Meeting notification | 2026-03-30 | English | ||
| 33089974 | 2026 Notice of AGM | 2026-03-30 | English | ||
| 33045671 | Preliminary results for the year ended 31 Dec 2025 | 2026-03-26 | English | ||
| 32970907 | Licensing agreement with VVMF | 2026-03-18 | English | ||
| 32916724 | Admission to Trading | 2026-03-09 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Oxford Biomedica PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aprogen Biologics Inc.
Develops and manufactures novel biologics and biosimilar an…
|
003060 | KR | Manufacturing |
|
Aprogen, Inc
Develops and manufactures biologic medicines, including bio…
|
007460 | KR | Manufacturing |
|
Aptabio Therapeutics Inc.
Develops drugs for intractable diseases by regulating oxida…
|
293780 | KR | Manufacturing |
|
Aptamer Sciences Inc
Clinical-stage company developing aptamer-based therapeutic…
|
291650 | KR | Manufacturing |
|
Aptorum Group Ltd
Clinical-stage biopharma developing therapeutics for oncolo…
|
APM | US | Manufacturing |
|
Aptus Pharma Limited
Develops and manufactures cardiovascular, metabolic, and ga…
|
544529 | IN | Manufacturing |
|
Aquestive Therapeutics, Inc.
Pharmaceutical company developing oral film medicines for C…
|
AQST | US | Manufacturing |
|
Arbutus Biopharma Corp
Clinical-stage biopharma company developing a functional cu…
|
ABUS | US | Manufacturing |
|
Arcellx, Inc.
A clinical-stage biotech company developing immunotherapies…
|
ACLX | US | Manufacturing |
|
Arctic Bioscience
Develops pharmaceutical and nutraceutical products from mar…
|
ABS | NO | Manufacturing |
Oxford Biomedica PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/5190/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=5190 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=5190 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=5190 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 5190}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oxford Biomedica PLC (id: 5190)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.